Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine versus midazolam plus fentanyl for ICU sedation in intracerebral hemorrhage
IRCT20260707070094N1Phase 3Recruiting
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of dexmedetomidine, midazolam and fentanyl in intracerebral hemorrhage (ICH) (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoint: Sedation efficacy through physician satisfaction. Started Nov 2026; status: recruiting.
02
Drugs
dexmedetomidinemidazolamfentanyl
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on IRCT20260707070094N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260707070094N1.